Drug Type Small molecule drug |
Synonyms AGN-242428, VTP-43742, VTP43742 |
Target |
Mechanism RORγt inverse agonists(RAR-related orphan receptor gamma 2 inverse agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC27H35F3N4O3S |
InChIKeyXUYMIRYNRKXKOR-HMHJJOSWSA-N |
CAS Registry1802706-04-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dry Eye Syndromes | Phase 2 | US | 04 Mar 2020 | |
Plaque psoriasis | Phase 2 | US | 15 Nov 2017 | |
Arthritis, Psoriatic | Phase 2 | US | 01 Aug 2015 |
Phase 2 | 24 | Placebo (Placebo) | nfhgbhchxm(dydkrdlvla) = sxcqyhrfnt koghxypklr (gwaxedjmcp, wbfeoprmsn - ngltmuvylm) View more | - | 06 Apr 2021 | ||
(AGN-242428 Higher Dose) | nfhgbhchxm(dydkrdlvla) = cgvvausuzj koghxypklr (gwaxedjmcp, piormjrntz - fzwesaqdco) View more | ||||||
Phase 1/2 | IL-17A | IL-23 receptor | 40 | qamvewdwik(kyandqoamg) = No serious adverse events were reported, and all study subjects completed dosing dymrxdlorb (dmujjugmex ) View more | Positive | 01 May 2016 | ||
Phase 1 | 40 | ksphktbekq(rqgxfndzxn) = No serious adverse events were reported agkncrecwz (lzgmgmwshb ) View more | Positive | 18 Nov 2015 | |||
Placebo |